Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study investigated alopecia areata in a mouse model, finding that tofacitinib may inhibit disease progression by modulating linoleic acid metabolism and magnesium pathways, particularly affecting CD8+ T cell infiltration in hair follicles, offering insights for potential treatments.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

In this retrospective study, tofacitinib showed promise as a treatment for alopecia areata, with 46.5% of patients experiencing a very good response and minimal adverse effects, suggesting it could be a primary option for moderate to severe cases.

This report details the case of an 11-year-old girl with APECED syndrome carrying a unique homozygous mutation in the AIRE gene, the first of its kind documented.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.

This study found that tofacitinib may be effective for treating pediatric rheumatic diseases, with especially promising results in patients with autoinflammatory diseases, arthritis and alopecia, and juvenile dermatomyositis.

This study successfully synthesized acetyl tetrapeptide-3 on a laboratory scale with over 56% yield and 100% purity, supporting its use in developing hair loss and scalp care products.

In this study, authors present a case where a 26-year-old patient with alopecia areata experienced relapse after initially responding to Tofacitinib, mitigated by corticosteroids, highlighting challenges and potential insights into the treatment and pathogenesis of the condition.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This study found that a 671-base pair promoter sequence from the ultra-high-sulfur keratin gene is sufficient to direct tissue-specific and development-specific expression of a reporter gene during hair growth in transgenic mice.

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.

In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

This report documents a 14-year-old Chinese boy with mitochondrial encephalopathy, lactic acidosis, stroke-like episodes, and a de novo A3243G mitochondrial DNA mutation, highlighting the condition's multisystem involvement without ragged red fibers in muscle biopsy.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This study found that ATP may help reduce ribociclib-induced skin damage in rats by mitigating biochemical changes associated with oxidative stress.

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.

This study describes the patterns of clinical response in patients with severe alopecia areata treated with baricitinib over 52 weeks, based on integrated data from two Phase 3 trials.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

Tofacitinib may help hair regrowth in alopecia areata, but more research is needed.

This study found that the ethyl acetate extract of Semecarpus anacardium leaves demonstrated cytotoxicity against MCF-7 cancer cells and induced apoptosis, suggesting potential as a cancer treatment with fewer side effects.

AC-5216 reduces anxiety in mice through neurosteroids affecting GABAA receptors.

This study presents the first report on cloning and characterizing the full-length cDNA of SRD5A1 in Indian catfish (Clarias magur), revealing expression differences across reproductive phases and increased expression post-Ovatide administration in ovaries and testis.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

In this study, researchers identified a cluster of hair-specific keratin-associated protein genes within the 21q22.3 region, revealing a novel transcription mechanism involving TSPEAR/C21orf29 that may bypass typical transcriptional termination sites.

The article in Dermatologic Therapy discusses clinical experiences with using tofacitinib to treat alopecia areata in 63 patients, but no specific results are reported in the abstract.

This study investigated a patient with spinal and bulbar muscular atrophy who had 68 CAG repeats, revealing early onset and unique symptoms not previously documented in the condition.

In this case report, a novel heterozygous mutation in the insulin receptor gene was identified in an adolescent girl with type A insulin resistance syndrome, characterized by excessive hair growth and skin changes, and her mother.